{"nctId":"NCT00687739","briefTitle":"Prevention of Obesity in Women Via Estradiol Regulation","startDateStruct":{"date":"2008-05"},"conditions":["Obesity"],"count":79,"armGroups":[{"label":"1","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: leuprolide acetate"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: leuprolide acetate","Behavioral: progressive resistance exercise training"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: leuprolide acetate","Drug: Estradiol Transdermal"]},{"label":"4","type":"EXPERIMENTAL","interventionNames":["Drug: leuprolide acetate","Drug: Estradiol Transdermal","Behavioral: progressive resistance exercise training"]}],"interventions":[{"name":"leuprolide acetate","otherNames":["Lupron"]},{"name":"Estradiol Transdermal","otherNames":["Climara"]},{"name":"progressive resistance exercise training","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy premenopausal women, aged 18 to 49 years\n* Regular menses (no missed cycles in previous year; cycle length 25-35 days)\n* Positive luteinizing hormone test or a mid-luteal serum progesterone greater than 3 ng/mL\n* Nonsmokers\n* Willing to receive all study interventions\n* Physically able and willing to be randomized to participate in a supervised resistance exercise training program\n\nExclusion Criteria:\n\n* Already performing high-intensity resistance exercise training more than 1 day per week\n* On diabetes medications\n* Use of hormonal contraception in the past 3 months\n* On oral or inhaled glucocorticoids\n* Positive pregnancy test\n* Intention to become pregnant or start hormonal contraceptive therapy during the period of study\n* Lactation\n* Hypersensitivity to extrinsic peptide hormones, mannitol, Gonadotropin-releasing hormone (GnRH), leuprolide acetate, benzyl alcohol (the vehicle for injection of leuprolide acetate), or transdermal patch\n* Score greater than 16 on the Center for Epidemiologic Studies Depression Scale and Beck Depression Inventory-II score greater than 18, or clinician recommendation to exclude\n* Severe osteopenia or osteoporosis (proximal femur or lumbar spine t scores \\< -2.0)\n* BMI greater than 40 kg/m2, weight change of more than Â± 2 kg in last 6 months, or weight-reduced by more than 5 kg from maximal body weight\n* Abnormal vaginal bleeding\n* History of breast cancer or other estrogen-dependent neoplasms\n* History of venous thromboembolic events\n* Moderate or severe renal impairment (creatinine clearance \\<50 mL/min by Cockcroft-Gault)\n* Chronic hepatobiliary disease, defined as liver function tests (AST, ALT, alkaline phosphatase, total bilirubin) greater than 1.5 times the upper limit of normal\n* Thyroid dysfunction, defined as ultra sensitive TSH less than 0.5 or greater than 5.0 mU/L\n* Uncontrolled hypertension, defined as resting BP greater than 150/90 mmHg\n* Cardiovascular disease, including indicators of ischemic heart disease or serious arrhythmias at rest or during the graded exercise test; follow-up diagnostic testing to rule out cardiovascular disease by a cardiologist will be allowed\n* Orthopedic or other problems that would interfere with participation in the exercise program","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Resting Energy Expenditure (REE)","description":"Resting energy expenditure measured by indirect calorimeter at baseline and after 5 months of treatment.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.8","spread":null},{"groupId":"OG001","value":"-87.2","spread":null},{"groupId":"OG002","value":"14.6","spread":null},{"groupId":"OG003","value":"-19.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Cortisol Response (Area Under the Curve) to CRH Under DEX Suppression","description":"Cortisol response to corticotropin releasing hormone (CRH) during dexamethasone (DEX) suppression; DEX/CRH stimulation test","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"-3115","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Energy Expenditure (TEE)","description":"24-hour energy expenditure measured by indirect calorimetry in a room calorimeter","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-108.8","spread":null},{"groupId":"OG001","value":"-166.5","spread":null},{"groupId":"OG002","value":"-92.7","spread":null},{"groupId":"OG003","value":"-107.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Fat Mass","description":"Total body fat mass measured by DXA","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"-0.6","spread":null},{"groupId":"OG002","value":"0.4","spread":null},{"groupId":"OG003","value":"-0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Fat-free Mass","description":"Total body fat-free mass measured by DXA","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":null},{"groupId":"OG001","value":"0.1","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"1.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":[]}}}